Natural cold remedy Ridovir Cold, from Quebec-based Biopharmacopae, is slated to roll out to retail pharmacies in Canada.


Ridovir Cold, Biopharmacopae, natural cold remedy, cough and cold symptoms, Johane Guay, Zellers, Rexall, Pharma Plus, cold/cough medicine






























































































































































































































INSIDE THIS ISSUE
News
Opinion
Other Services
Reprints / E-Prints
Submit News
White Papers

Supplier News Breaks Archives

Ridovir Cold to hit pharmacy shelves in Canada

November 12th, 2010

QUEBEC CITY, Quebec – Natural cold remedy Ridovir Cold, from Quebec-based Biopharmacopae, is slated to roll out to retail pharmacies in Canada.

Biopharmacopae said this week that Ridovir Cold will soon be available at Zellers, Rexall drug stores, Pharma Plus drug marts and other pharmacies in Canada.

According to the company, Ridovir Cold provides a new, natural and effective way to help relieve cough and cold symptoms, targeting several aspects of the cold at the same time. The cold/cough medicine, available in pharmacies in 12-count blister packs and 45-count bottles, can be used as an intensive treatment at the onset of cold symptoms or as a preventive treatment when needed.

Ridovir Cold contains two extracts derived from ginger and goldenrod, plants that are already known for other health benefits and have a well-documented history of safety, according to Biopharmacopae.

"Our scientific team discovered that, when combined using a specific technology process, these plants can effectively inhibit the activity of viruses responsible for causing colds (rhinoviruses) and the flu (influenza virus)," stated Dr. Johane Guay, Ph.D., president and chief executive officer of Biopharmacopae.

Biopharmacopae noted that Ridovir Cold is the result of years of research and was first tested in the hope of improving the quality of life of cancer patients. Additional tests found that volunteers experienced a significant decrease in the occurrence and intensity of coughs and colds. That prompted the company to undertake additional in vitro and in vivo research to demonstrate the antiviral activity of the product, and the conclusive results of the studies led to the filing of a patent and to the manufacturing of the product for commercial use, Biopharmacopae said.

Advertisement